Jamil Khurram sold 568 shares of GALECTIN THERAPEUTICS INC at $3.10 for −$1.76k on May 26, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Chief Medical Officer
Chief Medical Officer
Filed May 28, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$1,761.03Shares × reported price
Shares traded
568Common Stock
Price per share
$3.10Reported price. Read footnotes for ranges.
% of reported position traded
100%This security and ownership context
Holdings after
0Direct
Trade date
May 26, 2026Sell
Filed
May 28, 2026, 9:13 AM ET2-day reporting delay
Accession
0001133416-26-000055Code S · Transaction 387229
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 568 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
May 26, 2026Option exercise568$1.23$698.64Trade 387228
May 26, 2026Option exercise568$0.00$0Trade 387230
3 transaction rows in this filing. Joint filers share the same rows.

GALT price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
GALT · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −9.3%1w ago −19%1d ago −2.7%
Returns since7d −7.4%30d +94%90d +61%180d1y

Footnotes in full

F1: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 F2: The shares were sold in multiple transactions at prices ranging from $3.00 to $3.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. F3: The options vest as follows: 16,250 on each of June 30, 2025, December 31, 2025, June 30, 2026, and December 31, 2026.